Cargando…
Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224778/ https://www.ncbi.nlm.nih.gov/pubmed/28096995 http://dx.doi.org/10.1002/ccr3.749 |